

**Annexure - I**

**Requirement of HIV-1 subtype C Vaccine Constructs (rDNA)**

S. No	Details	Total Req. with 40% Extra	Concentrations and vials								
<b>Plasmid Based Constructs ( Conc. / Vial x No. of Vials )</b>											
1	pNK14	251.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	3.2 mg x 3
2	NK49426CO	270.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	6.4 mg X 3
3	NK49587CO	270.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	6.4 mg X 3
4	NK-IND- <i>nef</i> CO	270.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	6.4 mg X 3
5	NK-IND- <i>tat</i> CO	270.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	6.4 mg X 3
6	NK49426CO	270.0 mg	2.0mg X 4	24.0 mg X 4	1.1mg X 5	2.8 mg X 5	5.5mg X 5	2.1mg X 5	5.3 mg X 5	10.5mg X 5	6.4 mg X 3
<b>Total Requirement</b>		<b>1.600 g</b>	<b>48.0 mg</b>	<b>576.0 mg</b>	<b>33.0 mg</b>	<b>84.0 mg</b>	<b>165.0 mg</b>	<b>63.0 mg</b>	<b>159.0 mg</b>	<b>315.0 mg</b>	<b>106.0 mg</b>
<b>Justification for 40% Extra: 25% spillage + 15% archiving</b>											

**Annexure - II**

**Requirement of HIV-1 subtype C Vaccine Constructs (rMVA)**

S. No	Details	Total Req. with 40% Extra	Concentrations and vials								
<b>Modified Vaccinia Ankara Virus (x10<sup>8</sup> pfu)</b>											
1	MVA	243.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml) X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(4.0 x 10 <sup>8</sup> /2.0 ml) X 2
2	VV29692CO	259.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml)X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(8.0 x 10 <sup>8</sup> /4.0 ml) X 2
3	VV49426CO	259.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml)X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(8.0 x 10 <sup>8</sup> /4.0 ml) X 2
4	VV49597CO	259.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml)X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(8.0 x 10 <sup>8</sup> /4.0 ml) X 2
5	VV-IND- <i>nef</i> CO	259.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml)X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(8.0 x 10 <sup>8</sup> /4.0 ml) X 2
6	VV-IND- <i>tat</i> CO	259.0x10 <sup>8</sup> pfu	(2x10 <sup>8</sup> /0.5 ml)X4	(30x10 <sup>8</sup> /3.0ml) X 4	(1.5x10 <sup>8</sup> /1.2ml) X 3	(4x10 <sup>8</sup> /1.2ml) X 3	(7x10 <sup>8</sup> /1.2ml) X 3	(3x10 <sup>8</sup> /3.0ml) X 3	(7x10 <sup>8</sup> /3.0ml) X 3	(13x10 <sup>8</sup> /3.0ml) X 3	(8.0 x 10 <sup>8</sup> /4.0 ml) X 2
<b>Total Requirement</b>		<b>155 x10<sup>9</sup> pfu</b>	<b>48x10<sup>8</sup>pfu / 12.0 ml</b>	<b>720x10<sup>8</sup>pfu /72.0 ml</b>	<b>27x10<sup>8</sup>pfu / 21.6 ml</b>	<b>72x10<sup>8</sup>pfu / 21.6 ml</b>	<b>126x10<sup>8</sup>pfu / 21.6 ml</b>	<b>54x10<sup>8</sup> pfu/ 54.0 ml</b>	<b>126x10<sup>8</sup>pfu / 54.0 ml</b>	<b>234x10<sup>8</sup>pfu / 54.0 ml</b>	<b>88.0 x 10<sup>8</sup> pfu / 44.0 ml</b>
<b>Justification for 40% Extra: 25% spillage + 15% archiving</b>											